arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Cencora, Inc.

COR Health Care Other Pharmaceuticals
$331.69
▲ +0.2% Today
as of Sep 4, 16:47 ET
Last 30 days +6.36% Jul 27 → Sep 04
$303.80 $312.78 $321.75 $330.72 $339.70 Jul 27 Aug 04 Aug 12 Aug 19 Aug 27 Sep 04
Open
$333.48
High
$336.01
Low
$330.20
Volume
$1M
Avg Vol
$2M
Mkt Cap
$59.2B
P/E (TTM)
21.17
Beta
—
52w High
$377.54
52w Low
$244.82
Div Yield
—
Shares Out
$191M

Recent Press Releases & News last 60 days · 25 items

mixed ▲ 3 ● 22 ▼ 0
Sep 4 · 19:39 Zacks neutral
Here's Why You Should Retain Cencora Stock in Your Portfolio for Now
Sep 4 · 15:30 Zacks neutral
Cencora (COR) Up 3.8% Since Last Earnings Report: Can It Continue?
Sep 4 · 13:37 PRODUCT Zacks bullish
Cencora Launches Cell and Gene Therapy Enablement for Health Systems
▸ Show all 25 press releases & news Free account →

Overview

52-week range
$245
$378
65% of range
Avg surprise (last 3)
+4.4%
Avg reaction (last 2)
-6.3%
50% positive
Latest IV / EM
22%
EM ±3.5% · $330 · Sep 18

Earnings trends

EPS — actual vs estimate Actual Estimate
$2.09$2.77$3.44$4.12$4.80 Actual $2.13Actual $2.35Actual $2.98Actual $2.09Actual $2.42Actual $2.50Actual $4.42Est $4.08Actual $4.00Est $3.78Actual $2.87Actual $4.75Est $4.80Actual $3.94 MarJunDecMarJunDecMar/2025Jun/2025DecMar/2026Jun
Revenue vs Net Income Revenue Net income
$0$22.6B$45.1B$67.7B$90.2B Dec 24Mar 25Jun 25Dec 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $3.94 — — — — financials
Wed May 6, 2026Mar/2026 $4.75 $4.80 -1.0% +7.5% -17.4% earnings
Wed Dec 31, 2025Dec 2025 $2.87 — — — — financials
Wed Aug 6, 2025Jun/2025 $4.00 $3.78 +5.8% — — earnings
Wed May 7, 2025Mar/2025 $4.42 $4.08 +8.3% — +4.7% earnings
Tue Dec 31, 2024Dec 2024 $2.50 — — — — financials
Sun Jun 30, 2024Jun 2024 $2.42 — — — — financials
Sun Mar 31, 2024Mar 2024 $2.09 — — — — financials
Sun Dec 31, 2023Dec 2023 $2.98 — — — — financials
Fri Jun 30, 2023Jun 2023 $2.35 — — — — financials
Fri Mar 31, 2023Mar 2023 $2.13 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$84.75B$78.36B$85.93B—$80.66B$75.45B$81.49B—
Cost of revenue$81.15B$74.77B$82.86B—$77.76B$72.39B$78.93B—
Gross profit$3.61B$3.59B$3.07B—$2.91B$3.06B$2.56B—
Operating income$1.12B$1.14B$760M—$868M$1.04B$706M—
Net income$764M$1.64B$560M—$687M$718M$489M—
EPS (diluted)$3.94$8.40$2.87—$3.52$3.68$2.50—

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$2.82B$2.18B$1.75B$4.36B$2.23B$1.98B$3.22B$3.13B
Inventory$21.03B$20.01B$24.08B$20.49B$20.14B$18.97B$20.51B$19.00B
Total current assets$55.34B$53.14B$54.15B$52.24B$48.81B$46.53B$49.99B$47.72B
Total assets$83.81B$81.65B$78.36B$76.59B$73.96B$71.19B$69.05B$67.10B
Long-term debt$11.44B$12.18B$7.58B$7.54B$8.04B$7.09B$5.94B$3.81B
Total liabilities————————
Total equity$3.05B$3.58B$2.10B$1.51B$2.21B$1.18B$362M$646M

Implied volatility — last 90 days

22%28%35%42%48% Jun 07 — IV 31% · EM ±4.3%Jun 08 — IV 33% · EM ±4.4%Jun 09 — IV 32% · EM ±4.0%Jun 10 — IV 35% · EM ±4.1%Jun 11 — IV 31% · EM ±3.4%Jun 12 — IV 27% · EM ±2.7%Jun 15 — IV 30% · EM ±2.2%Jun 16 — IV 31% · EM ±1.8%Jun 17 — IV 40% · EM ±1.7%Jun 19 — IV 28% · EM ±6.1%Jun 22 — IV 28% · EM ±5.8%Jun 23 — IV 26% · EM ±5.3%Jun 24 — IV 27% · EM ±5.5%Jun 25 — IV 25% · EM ±5.0%Jun 26 — IV 25% · EM ±4.7%Jun 29 — IV 27% · EM ±4.8%Jun 30 — IV 28% · EM ±4.8%Jul 01 — IV 27% · EM ±4.5%Jul 02 — IV 24% · EM ±4.0%Jul 03 — IV 25% · EM ±3.9%Jul 06 — IV 28% · EM ±3.8%Jul 07 — IV 31% · EM ±4.1%Jul 08 — IV 27% · EM ±3.3%Jul 09 — IV 26% · EM ±3.1%Jul 10 — IV 25% · EM ±2.7%Jul 13 — IV 33% · EM ±2.7%Jul 14 — IV 30% · EM ±2.2%Jul 15 — IV 45% · EM ±2.6%Jul 16 — IV 49% · EM ±2.0%Jul 20 — IV 36% · EM ±8.5%Jul 21 — IV 36% · EM ±8.3%Jul 22 — IV 36% · EM ±8.3%Jul 23 — IV 36% · EM ±8.0%Jul 24 — IV 35% · EM ±7.8%Jul 27 — IV 38% · EM ±7.9%Jul 28 — IV 38% · EM ±7.7%Jul 29 — IV 39% · EM ±7.8%Jul 30 — IV 39% · EM ±7.6%Jul 31 — IV 40% · EM ±7.7%Aug 03 — IV 42% · EM ±7.4%Aug 04 — IV 47% · EM ±8.1%Aug 05 — IV 28% · EM ±4.7%Aug 06 — IV 26% · EM ±4.2%Aug 07 — IV 24% · EM ±3.7%Aug 10 — IV 27% · EM ±3.7%Aug 11 — IV 25% · EM ±3.3%Aug 12 — IV 27% · EM ±3.3%Aug 13 — IV 28% · EM ±3.3%Aug 14 — IV 26% · EM ±2.9%Aug 17 — IV 32% · EM ±2.7%Aug 18 — IV 29% · EM ±2.1%Aug 19 — IV 33% · EM ±2.0%Aug 20 — IV 48% · EM ±2.0%Aug 24 — IV 25% · EM ±5.2%Aug 25 — IV 25% · EM ±5.1%Aug 26 — IV 23% · EM ±4.7%Aug 27 — IV 24% · EM ±4.6%Aug 28 — IV 24% · EM ±4.5%Aug 31 — IV 25% · EM ±4.4%Sep 01 — IV 23% · EM ±3.9%Sep 02 — IV 22% · EM ±3.8%Sep 03 — IV 23% · EM ±3.8%Sep 04 — IV 22% · EM ±3.5%

Sector peers

LLY
Eli Lilly and Company
$1.1T $1,148.00-0.1%
JNJ
Johnson & Johnson
$671.0B $275.71+0.2%
ABBV
AbbVie Inc.
$430.9B $256.50+0.1%
MRK
Merck & Company, Inc.
$317.1B $150.33+0.0%
PM
Philip Morris International Inc
$299.3B $182.53+0.0%
NVS
Novartis AG
$297.9B $155.11-3.0%
View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in